Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in
patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75
response rate at Week 12.